Allogene Therapeutics | search
Click here to view Allogene Therapeutics news from 60+ newspapers.
Bookmark or Share- About Us - AllogeneLEARN ABOUT AlloCAR T™. Allogene Therapeutics is a clinical-stage biotechnology company with a single-minded focus on pioneering the development of investigational allogeneic chimeric antigen receptor T cell (AlloCAR T™) products for cancer. Led by world-class management with significant experience in cell therapy, our fully integrated, in ...
- Home - AllogeneWE KNOW HOW TO GET THERE. Our mission is to create and lead the next revolution in cancer treatment by delivering to patients the first allogeneic CAR T cell (AlloCAR T™) products for blood cancers and solid tumors. LEARN HOW A SINGLE PRODUCTION RUN CAN YIELD TREATMENT FOR 100+ PATIENTS ».
- AlloCAR T™ Products - AllogeneALLOGENEIC CAR T —THE NEXT REVOLUTION IN CELL THERAPY. Allogene is working to overcome the limitations of autologous CAR T therapies by creating investigational allogeneic CAR T cell products, or AlloCAR T™ products. Unlike autologous cell therapy, AlloCAR T™ products use T cells from healthy donors. These cells are isolated in a ...
- Press Releases | Allogene TherapeuticsSOUTH SAN FRANCISCO, Calif. , Jan. 16, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in. Jan 04, 2024.
- Allogene Therapeutics Initiates Industry’s First Allogeneic CAR T Phase ...SOUTH SAN FRANCISCO, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced the initiation of the potentially pivotal Phase 2 clinical trial of ALLO-501A (ALPHA2 trial) in patients...
More
